TY - JOUR
T1 - A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity
AU - Perni, Michele
AU - Galvagnion, Céline
AU - Maltsev, Alexander
AU - Meisl, Georg
AU - Müller, Martin B D
AU - Challa, Pavan K
AU - Kirkegaard, Julius B
AU - Flagmeier, Patrick
AU - Cohen, Samuel I A
AU - Cascella, Roberta
AU - Chen, Serene W
AU - Limbocker, Ryan
AU - Sormanni, Pietro
AU - Heller, Gabriella T
AU - Aprile, Francesco A
AU - Cremades, Nunilo
AU - Cecchi, Cristina
AU - Chiti, Fabrizio
AU - Nollen, Ellen A A
AU - Knowles, Tuomas P J
AU - Vendruscolo, Michele
AU - Bax, Adriaan
AU - Zasloff, Michael
AU - Dobson, Christopher M
PY - 2017/2/7
Y1 - 2017/2/7
N2 - The self-assembly of α-synuclein is closely associated with Parkinson's disease and related syndromes. We show that squalamine, a natural product with known anticancer and antiviral activity, dramatically affects α-synuclein aggregation in vitro and in vivo. We elucidate the mechanism of action of squalamine by investigating its interaction with lipid vesicles, which are known to stimulate nucleation, and find that this compound displaces α-synuclein from the surfaces of such vesicles, thereby blocking the first steps in its aggregation process. We also show that squalamine almost completely suppresses the toxicity of α-synuclein oligomers in human neuroblastoma cells by inhibiting their interactions with lipid membranes. We further examine the effects of squalamine in a Caenorhabditis elegans strain overexpressing α-synuclein, observing a dramatic reduction of α-synuclein aggregation and an almost complete elimination of muscle paralysis. These findings suggest that squalamine could be a means of therapeutic intervention in Parkinson's disease and related conditions.
AB - The self-assembly of α-synuclein is closely associated with Parkinson's disease and related syndromes. We show that squalamine, a natural product with known anticancer and antiviral activity, dramatically affects α-synuclein aggregation in vitro and in vivo. We elucidate the mechanism of action of squalamine by investigating its interaction with lipid vesicles, which are known to stimulate nucleation, and find that this compound displaces α-synuclein from the surfaces of such vesicles, thereby blocking the first steps in its aggregation process. We also show that squalamine almost completely suppresses the toxicity of α-synuclein oligomers in human neuroblastoma cells by inhibiting their interactions with lipid membranes. We further examine the effects of squalamine in a Caenorhabditis elegans strain overexpressing α-synuclein, observing a dramatic reduction of α-synuclein aggregation and an almost complete elimination of muscle paralysis. These findings suggest that squalamine could be a means of therapeutic intervention in Parkinson's disease and related conditions.
KW - Algorithms
KW - Amino Acid Sequence
KW - Animals
KW - Animals, Genetically Modified
KW - Biological Products/chemistry
KW - Caenorhabditis elegans/genetics
KW - Cell Line, Tumor
KW - Cholestanols/chemistry
KW - Humans
KW - Membrane Lipids/chemistry
KW - Molecular Structure
KW - Neuroblastoma/metabolism
KW - Paresis/genetics
KW - Parkinson Disease/metabolism
KW - Protein Aggregates/drug effects
KW - Protein Aggregation, Pathological/prevention & control
KW - Protein Binding/drug effects
KW - Protein Multimerization/drug effects
KW - alpha-Synuclein/chemistry
U2 - 10.1073/pnas.1610586114
DO - 10.1073/pnas.1610586114
M3 - Journal article
C2 - 28096355
SN - 0027-8424
VL - 114
SP - E1009-E1017
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 6
ER -